Related Experiment Video
Updated: Dec 24, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Recapture Rate of Brodalumab in Patients With a Lapse in Treatment
Abstract:
The National Psoriasis Foundation has emphasized the importance of achieving skin clearance targets throughout the course of treatment. However, patients with psoriasis often stop and restart treatment for reasons such as psychological distress, dissatisfaction with treatment, inconvenience, cost, or comorbidities. Brodalumab is a fully human anti-interleukin-17 receptor A monoclonal antibody efficacious for the treatment of moderate-to-severe plaque psoriasis. This review discusses the efficacy and safety of brodalumab and other biologic therapies in patients with psoriasis who stop and restart treatment. These clinically relevant and important findings can help inform real-world treatment decisions. J Drugs Dermatol. 2020;19(4):384-387. doi:10.36849/JDD.2020.5026.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Therapeutic Drug Monitoring: Affecting Factors
Desensitization and Tachyphylaxis
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

